Mineralocorticoid receptor blockade in chronic kidney disease - PubMed (original) (raw)

Review

doi: 10.1159/000334161. Epub 2012 Jan 20.

Affiliations

Review

Mineralocorticoid receptor blockade in chronic kidney disease

Andrew S Bomback et al. Blood Purif. 2012.

Abstract

Mineralocorticoid receptor blockers (MRBs) have proven highly successful in the treatment of congestive heart failure and resistant hypertension. In contrast, their use in chronic kidney disease (CKD) has lagged due to the concern of hyperkalemia and, possibly, because of the incorrect assumption that traditional therapy with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers consistently reduce aldosterone activity in all patients. Low-dose MRB therapy may offer additional antihypertensive and unique anti-inflammatory benefits in select CKD populations.

Copyright © 2012 S. Karger AG, Basel.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources